General Metabolics (GMet) is excited to report that as of February 2020 it has contracted over 10,000 samples for non-targeted metabolomics analysis at its Boston laboratory. This includes a large cohort of 3,500 human plasma samples that GMet will analyze and integrate with the patient’s genomic data. “Having a US laboratory has allowed us to greatly increase our overall capacity and return time,” said Andrew Mullen, Ph.D., GMet’s Director of Operations, “Our typical customers have study sizes ranging from a few dozen samples to several thousand, and we are regularly returning data back to them in typically less than 2 weeks. We are optimizing our operations to shrink this gap even further.”
GMet’s Boston laboratory supports end-to-end metabolism research through non-targeted and targeted metabolomics methods. Please contact us if you would like to hear more about our capabilities.